{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Percentage of study participants who did not report that their multiple myeloma relapsed or progressed (got worse)","groups":[{"description":"Rituximab 375 mg/m\\^2 on Days -10 and -7; Cyclophosphamide 50 mg/kg on days -3, -2, -1, and 0; Rituximab 375 mg/m\\^2 weekly x4 after platelet counts recover; For patients achieving at least stable disease, rituximab maintenance 375 mg/m\\^2 once each during months 3, 6, 9, and 12","id":"OG000","title":"Rituximab + Cyclophosphamide"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Event-free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}